DR. FATIHA HANA SHABARUDDIN

Wong XZ, Azzeri A, Gan CC, Shabaruddin FH, Dahlui M, Yahya R, Ganapathy S, Tan SS, Mohamed R, Lim SK (2021) Hepatitis C virus core antigen as alternative diagnostic algorithm for active hepatitis C virus infection among haemodialysis population: Cost implications. Nephrology [early view] DOI: https://doi.org/10.1111/nep.13862

Hiebert L, Azzeri A, Dahlui M, Hecht R, Mohamed R, Shabaruddin FH, & McDonald SA (2020) Estimating the Population Size of People Who Inject Drugs in Malaysia for 2014 and 2017 Using the Benchmark-Multiplier Method. Substance Use and Misuse https://doi.org/10.1080/10826084.2019.1708943

Kubas MA, Shabaruddin FH, Mazlan-Kepli W, Jagan N, Mohamed S, Nazar NIM, Zin CS (2020) Assessing adherence and persistence to non-vitamin K antagonist oral anticoagulants (NOACs) among patients with atrial fibrillation in tertiary-care referral centers in Malaysia. Journal of Pharmacy and BioAllied Sciences 12(6):781-786 DOI: 10.4103/jpbs.JPBS_381_19

Hiebert L, Hecht R, Soe-Lin S, Mohamed R, Shabaruddin FH, Syed Mansor SM, Dahlui M, Azzeri A, McDonald SA (2019) A Stepwise Approach to a National Hepatitis C Screening Strategy in Malaysia to Meet the WHO 2030 Targets: Proposed Strategy, Coverage, and Costs. Value in Health Regional Issues 18: 112-120

Mohamed R, Shabaruddin FH, Azzeri A, McDonald SA, Dahlui M (2019) Hepatitis C elimination by 2030 in Malaysia: an achievable goal? Journal of Virus Eradication 5:253

Snyder SR, Hao J, Cavallari LH, Geng Z, Elsey A, Johnson JA, Mohamed Z, Chaiyakunapruk N, Chong HY, Dahlui M, Shabaruddin FH, Patrinos GP, Mitropoulou C & Williams MS (2019) Generic Cost-Effectiveness Models: A Proof of Concept of a Tool for Informed Decision-Making for Public Health Precision Medicine. Public Health Genomics 21(5-6):217-227 doi: 10.1159/000500725

Azzeri A, Shabaruddin FH, Tan SS, Dahlui M, McDonald SA, Kamarulzaman A & Mohamed R (2018) Clinical Characteristics Of Patients With Chronic Hepatitis C Infection At Initial Presentation To Tertiary Care In An Asian Middle-Income Country. Southeast Asian Journal of Tropical Medicine and Public Health 49(5): 789 - 798

Lim KK, Yoon SY, Mohd Taib NA, Shabaruddin FH, Dahlui M, Woo YL, Thong MK, Teo SH, Chaiyakunapruk N (2018) Is BRCA Mutation Testing Cost Effective for Early Stage Breast Cancer Patients compared to Routine Clinical Surveillance? The case of an upper middle-income country in Asia. Applied Health Economics and Health Policy 16(3):395 - 406 doi 10.1007/s40258-018-0384-8 http://rdcu.be/JIJr

McDonald SA, Azzeri A, Shabaruddin FH, Dahlui M, Tan SS, Kamarulzaman A & Mohamed R (2018) Projections of the Healthcare Costs and Disease Burden due to Hepatitis C Infection under Different Treatment Policies in Malaysia, 2018-2040. Appl Health Econ Health Policy 16(6): 847 - 857

Pok SL, Shabaruddin FH, Dahlui M, Sockalingam S, Said MS, Rosman A, Lau IS, Isa LM, Hussain H, Ng CT, Mahadeva S (2018) Clinical and economic implications of upper gastrointestinal adverse events in Asian rheumatological patients on long-term non-steroidal anti-inflammatory drugs. International Journal of Rheumatic Diseases 21(5):943 - 951 doi: 10.1111/1756-185X.13256

Pok SL, Shabaruddin FH, Dahlui M, Sockalingam S, Said MS, Rosman A, Lau IS, Isa LM, Hussain H, Ng CT, Mahadeva S (2018). Risk of upper gastrointestinal adverse events in Malaysian rheumatic patients on long-term non-steroidal anti-inflammatory drugs. International Journal of Clinical Rheumatology, 13(3), 172-178

Chong HY, Mohamed Z, Tan LL, Wu DB, Shabaruddin FH, Dahlui M, Apalasamy YD, Snyder SR, Williams MS, Hao J, Cavallari LH & Chaiyakunapruk N (2017) Is Universal HLA-B*15:02 Screening a Cost-Effective Option in an Ethnically-Diverse Population? A Case Study of Malaysia. British Journal of Dermatology 177(4):1102-1112 doi: 10.1111/bjd.15498

McDonald SA, Dahlui M, Mohamed R, Naning H, Shabaruddin FH, Kamarulzaman A (2015) Projections of the current and future disease burden of hepatitis C virus infection in Malaysia. PLoS One 10(6):e0128091. doi:10.1371/journal.pone.0128091

Shabaruddin FH, Fleeman N and Payne K (2015) Economic evaluations of personalized medicine: existing challenges and current developments. Pharmacogenomics and Personalized Medicine 8:115-126

Shabaruddin FH & Payne K (2014) Chapter 18 Evaluating the Cost-Effectiveness of Pharmacogenomics in Clinical Practice. Published in The Handbook of Personalized Medicine: Advances in Nanotechnology, Drug Delivery, and Therapy (edited by Dr. Ioannis S. Vizirianakis, Aristotle University of Thessaloniki, Greece) Publisher: Pan Stanford Publishing Pte. Ltd. ISBN 978-981-4411-19-6

Shabaruddin FH, Chen LC, Elliott RA and Payne K (2013) A systematic review of utility values for chemotherapy-related adverse events. Pharmacoeconomics 31(4):277-288

Payne K & Shabaruddin FH (2010) Cost-effectiveness analysis in pharmacogenomics. Pharmacogenomics 11(5):643-646

Shabaruddin FH, Elliott RA, Valle JW, Newman WG and Payne K (2010) Reply: Guesstimates are not good enough for determining what is happening in routine care. British Journal of Cancer 103(12): 1887-1888

Shabaruddin FH, Elliott RA, Valle JW, Newman WG and Payne K. (2010) Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom. British Journal of Cancer 103(3):315-323

Shabaruddin FH & Ngu K (2022) Breast Cancer Care in Malaysia: Access to Early Detection and Optimal Treatment. IDEAS Institute for Democracy And Economic Affairs, Policy Ideas No76, December 2022. - Policy Paper

Shabaruddin FH, Chai BS, Woo YL & Dahlui M (2016) Cost Variations of Inpatient, Daycare and Outpatient Hysteroscopy in A Tertiary-Care Hospital in Malaysia. Value in Health 19(7):A820 (ISI-cited publication), ISPOR 7th Asia-Pacific Conference, ISPOR (International) (04 Sep 2016 - 06 Sep 2016)

Shabaruddin FH, Jamil AA, Hashim H, Yunus RM & Mohamed R (2016) Patient Characteristics and Clinical Outcomes of Patients with Liver Cancer in a Tertiary-Care Hospital in Malaysia. Value in Health 19(7):A886 (ISI-cited publication), ISPOR 7th Asia-Pacific Conference, ISPOR (International) (04 Sep 2016 - 06 Sep 2016)

Shabaruddin FH, Tappenden P, Elliott RA and Payne K (2015) Identifying key drivers that influence the cost-effectiveness of pharmacogenetics: A case study of the UGT1A1 pharmacogenetic test. Public Health Genomics 18(S1):44-45 (ISI-cited publication), Golden Helix 2015 Symposia (12 Mar 2015)

Shabaruddin FH, Chen LC, Elliott RA and Payne K (2012) Utility values for chemotherapy-related adverse events: A review of the literature. Value in Health 15(7):A609 (ISI-cited publication), ISPOR Asia Pacific Conference 2012 (03 Sep 2012)

Shabaruddin FH, Elliott RA, Tappenden P and Payne K (2011) Cost-effectiveness of using the UGT1A1 pharmacogenetic test to reduce the incidence of irinotecan chemotherapy-related febrile neutropaenia. Value in Health 14(7):A251-A252 (ISI-cited publication), ISPOR European Congress 2011 (06 Nov 2011)

Shabaruddin FH, Elliott RA, Tappenden P and Payne K (2011) Economic evaluation of the UGT1A1 pharmacogenetic test to inform dose selection of irinotecan-based chemotherapy. Value in Health 14(7):A252 (ISI-cited publication), ISPOR European Congress 2011 (06 Nov 2011)

Shabaruddin FH & Davies LM (2011) Cost of delivering psychiatric inpatient care to mental health patients with psychosis and co-occuring substance use: A UK based study. Value in Health 14(7):A291 (ISI-cited publication), ISPOR European Congress 2011 (06 Nov 2011)

Shabaruddin FH, Elliott RA, Tappenden P and Payne K (2012) Assessing the costs and benefits of a pharmacogenetic test to reduce the incidence of adverse events. PharmacoEpidemiology and Drug Safety 21(1):118 (ISI-cited publication), Prescribing and Research in Medicines Management (PRIMM) Adverse Drug Reactions Conference 2011 (24 Jun 2011)

Shabaruddin FH, Elliott RA and Payne K (2010) Examining patient-based costs for irinotecan chemotherapy: UK practice-based micro-costing study. Value in Health 13(7):A261 (ISI-cited publication), ISPOR European Congress 2010 (01 Nov 2010)

Shabaruddin FH, Elliott RA, Valle JW, Newman WG and Payne K (2010) Clinical management and cost of chemotherapy-induced neutropaenia in colorectal cancer specialties. International Journal of Pharmacy Practice 18(S2):67-68, Royal Pharmaceutical Society Conference 2010 (01 Sep 2010)

Shabaruddin FH, Elliott RA, Valle JW, Saunders MP, Newman WG and Payne K (2009) Identifying structural uncertainty in economic models of cancer treatments: A case study of irinotecan in colorectal cancer. Value in Health 12(7):A289-A290 (ISI-cited publication), ISPOR European Congress 2009 (01 Nov 2009)

Shabaruddin FH, Elliott RA, Valle JW, Saunders MP, Newman WG and Payne K (2009) Current trends with pharmacogenetic testing in colorectal cancer specialties: Are pharmacists ready? International Journal of Pharmacy Practice 17(S1):A33-A34, Health Services Research and Pharmacy Practice Conference 2009 (01 Apr 2009)

Shabaruddin FH, Payne K and Elliott RA (2008) Checklists and guidelines for the economic evaluation of medicines: Which should pharmacists use? International Journal of Pharmacy Practice 16(S1):A24-A25, Health Services Research and Pharmacy Practice Conference 2008 (01 Apr 2008)

Azzeri A, Shabaruddin FH, Mohamed R, McDonald SA, Tan SS, Kamarulzaman A, Dahlui M (2017) Cost of Treatment for Chronic Hepatitis C Infection at a National Tertiary-Care Referral Centre in an Asian Middle-Income Country. Value in Health 20(9):A633 (ISI-cited publication), ISPOR 20th Annual European Congress, ISPOR (International) (04 Nov 2017 - 08 Nov 2017)

Azzeri A, Shabaruddin FH, Tan SS, McDonald SA, Dahlui M, Kamarulzaman A, Mohamed R,(2017) Clinical Characteristics Of Patients With Chronic Hepatitis C Infection At Initial Presentation To Tertiary Care In An Asian Middle-Income Country. Value in Health 20(9):A632 (ISI-cited publication), ISPOR 20th Annual European Congress, ISPOR (International) (04 Nov 2017 - 08 Nov 2017)

Pok SL, Shabaruddin FH, Teng JY, Dahlui M, Ng CT, Sockalingam S, Said MS, Rosman A, Lau IS, Isa LM, Hussain H, Mahadeva S (2017) Prevalence and Direct Healthcare Costs of Upper Gastrointestinal Adverse Events in Asian Rheumatic Patients on Long Term Non-steroidal Anti-inflammatory Drugs (NSAIDs), Annals of the Rheumatic Diseases 76(2)446 (ISI-cited publication), Annual European Congress of Rheumatology 2017, European League Against Rheumatism (EULAR) (International) (14 Jun 2017 - 17 Jun 2017)

Lim KK, Yoon SY, Teo SH, Mohd Taib NA, Shabaruddin FH, Dahlui M, Chaiyakunapruk N (2016) Cost Effectiveness of BRCA Mutation Testing for Early-Stage Breast Cancer Patients with Family History in Malaysia. Value in Health 19(7):A889 (ISI-cited publication), ISPOR 7th Asia-Pacific Conference, ISPOR (International) (04 Sep 2016 - 06 Sep 2016)

Pok SL, Shabaruddin FH, Teng JY, Ng CT, Sockalingam S, Said MS, Rosman A, Lau IS, Isa LM, Hussain H, Mahadeva S (2016) Non-steroidal Anti-inflammatory Drug (NSAID)-induced Gastrointestinal Adverse Effects in Adults with Chronic Rheumatological Disorders: A Multi-centre, Retrospective, Cohort Study (GUT 2016 abstract book p73), Annual Scientific Congress of the Malaysian Society of Gastroenterology and Hepatology (GUT 2016), Malaysian Society of Gastroenterology and Hepatology (National) (22 Jul 2016 - 24 Jul 2016)

Siow FS, Dahlui M, Taib NAM, Shabaruddin FH (2015) Treatment pathways of breast cancer patients treated at the University of Malaya Medical Centre. Malaysian Journal of Pharmacy 2(1):102, Malaysian Pharmaceutical Society: Pharmacy Scientific Conference 2015 (01 Nov 2015)

ZY Fann, M Dahlui, NAM Taib, FH Shabaruddin (2015) Clinical management of breast cancer patients receiving chemotherapy at the University of Malaya Medical Centre. Malaysian Journal of Pharmacy 2(1):94, Malaysian Pharmaceutical Society: Pharmacy Scientific Conference 2015 (01 Nov 2015)

Teng JY, Pok LSL, Mahadeva S, Shabaruddin FH (2015) The prevalence of adverse events due to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in rheumatology patients treated at the University of Malaya Medical Centre. Malaysian Journal of Pharmacy 2(1):103, Malaysian Pharmaceutical Society: Pharmacy Scientific Conference 2015 (01 Nov 2015)

Chong YT, Bustam AZ & Shabaruddin FH (2012) Adverse events profile and clinical management of Malaysian breast cancer patients on FEC+docetaxel chemotherapy. Malaysian Journal of Pharmacy 1(10):61, Malaysian Pharmaceutical Society: Pharmacy Scientific Conference 2012 (01 Nov 2012)

Goh QL, Bustam AZ & Shabaruddin FH (2012) The incidence and clinical management of adverse events due to FOLFOX chemotherapy in colorectal cancer patients. Malaysian Journal of Pharmacy 1(10):60-61 , Malaysian Pharmaceutical Society: Pharmacy Scientific Conference 2012 (01 Nov 2012)

Payne K & Shabaruddin FH (2011) Using expert opinion in economic evaluations: A case study of a pharmacogenetic test for irinotecan in colorectal cancer, Nordic Social Pharmacy and Health Services Research Conference 2011 (15 Jun 2011)

Shabaruddin FH, Elliott RA & Payne K (2010) Incorporating adverse events in economic models, Health Economic Study Group 2010 Conference (01 Jul 2010)

Shabaruddin FH, Elliott RA, Newman WG & Payne K (2008) Eliciting expert opinion to inform an economic evaluation of the UGT1A1 pharmacogenetic test, ESRC Economics of Genetic Technologies Seminar 2008 (01 Nov 2008)

Shabaruddin FH, Elliott RA, Newman WG & Payne K (2008) Using a national survey to ensure the clinical validity of an economic model: A case study of a pharmacogenetic service applied to oncology, ESRC Economics and Pharmacy Practice Seminar 2008 (01 Oct 2008)

(2016) Examiner for candidature defence of a Masters degree at the Faculty of Medicine, University of Malaya (2016) Utilization of Preventive Strategies For Nonsteroidal Anti- Inflammatory Drug (NSAID)-Induced Upper Gastrointestinal Events, (Internal Examiner)

(2016) Reviewer for research article submitted to the International Journal of Pharmacy Practice (2016), (Reviewer)

(2016) External examiner (2016) Masters thesis (research) submitted to the Faculty of Medicine and Health Sciences, Islamic Science University of Malaysia (USIM) Prospective Study of the Incidence of Paediatric Adverse Drug Reactions in the Hospital Setting and the Development of a relevant App, (External Examiner)

(2016) Reviewer for research abstracts submitted to the ISPOR 7th Asia-Pacific Conference (2016), (Reviewer)

(2016) Committee member of Ministry of Health Malaysia's PharmacoEconomic Guideline for Malaysia 2019 , (Advisory Committee)

(2015) Examiner for candidature defence of a PhD submitted to the Faculty of Medicine, University of Malaya (2015) Evaluation of the relationship between medications and falls among older adults., (Internal Examiner)

(2015) Reviewer for research abstracts submitted to the Faculty of Medicine 2015 Research Week, University of Malaya (2015), (Reviewer)

(2014) Reviewer for research abstracts submitted to the ISPOR 6th Asia-Pacific Conference (2014), (Reviewer)

(2013) Reviewer for research articles submitted to the International Journal of Pharmacy Practice (2013 & 2014), (Reviewer)

(2013) Reviewer for research article submitted to Applied Health Economics and Health Policy (2013), (Reviewer)

(2012) Reviewer for research article submitted to Journal of the Royal Society Interface (2012), (Reviewer)

(2012) Reviewer for research abstracts submitted to the Malaysian Pharmaceutical Society: Pharmacy Scientific Conference (2012), (Reviewer)

(2012) Reviewer for research abstracts submitted to the ISPOR 5th Asia-Pacific Conference (2012), (Reviewer)

(2012) Reviewer for research article submitted to the journal Expert Opinion on Drug Delivery (2012), (Reviewer)

(2011) Reviewer for research articles submitted to The European Journal of Health Economics (2011 & 2012), (Reviewer)